Citius Pharmaceuticals Inc (CTXR) Live Share Price, Invest From India

Citius Pharmaceuticals Inc Stock Performance

as on January 1, 2026 at 2:29 am IST

Day's High
$0.76
Day's Price Range
$0.8
$0.76
5.26%
Upside
52 Week's Low
52 Week's High
$0.63
52-Week Price Range
$4.51
$0.76
17.11%
Downside
493.42%
Upside

Citius Pharmaceuticals Inc share price movements today

Previous Close: $0.78
Open: $0.78
Volume: 802.3K
Day's Low - High: $0.76 - $0.8
52 Week Low - High: $0.63 - $4.51

Citius Pharmaceuticals Inc Historical Returns

1 Month Return: -38.33 %
3 Month Return: -41.58 %
1 Year Return: -79.97 %
3 Year Return: -96.07 %
5 Year Return: -96.95 %

Citius Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Citius Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$16.1M

EPS (TTM)

1.9

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-38.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-52.42%

Citius Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Citius Pharmaceuticals Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Citius Pharmaceuticals Inc	BUY	$16.1M	-96.95%	NA	0.00%
Insmed Incorporated	BUY	$37.1B	422.8%	-16.34	-264.83%
Alnylam Pharmaceuticals, Inc.	BUY	$52.5B	205.96%	1242.66	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$116.2B	91.83%	31.93	31.35%
Regeneron Pharmaceuticals, Inc.	BUY	$81.8B	59.77%	18.48	32.13%

Stock Returns calculator for Citius Pharmaceuticals Inc Stock including INR - Dollar returns

The Citius Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Citius Pharmaceuticals Inc investment value today

Current value as on today

₹24,715

Returns

₹75,285

(-75.28%)

Returns from Citius Pharmaceuticals Inc Stock

₹80,412 (-80.41%)

Dollar Returns*

₹5,128 (+5.13%)

Analyst Recommendation on Citius Pharmaceuticals Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Citius Pharmaceuticals Inc. Average target price of $6

Citius Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Citius Pharmaceuticals Inc.

What analysts predicted

87.33%UPSIDE

Target Price

Current Price

$0.76

Analyzed by

9 Analysts

Target

$6.00

Citius Pharmaceuticals Inc target price $6, a slight upside of 87.33% compared to current price of $0.76. According to 9 analysts rating.

Citius Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Citius Pharmaceuticals Inc Stock has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Time period: December 3, 2025 to January 2, 2026

Change:-43% versus previous 30 day period

Citius Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	-	-	-	0	0	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	-
Operating Income	-8	-10	-9	-10	-10	-11	-10	-11	-8	-8
EBITDA	-8	-10	-9	-10	-10	-10	-9	-11	-8	-
Interest Expense	-	4	-	-	-	-	-	-	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-9	-9	-8	-10	-10	-10	-11	-8	-8
Income Tax Expense	0	0	0	0	0	0	0	0	0	-
Net Income	-8	-9	-9	-8	-10	-10	-9	-10	-8	-7
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-6920.05%	-6264.67%	0.00%	0.00%	0.00%

Citius Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	-
Operating Income	-7	-9	-13	-15	-17	-23	-33	-36	-41	-38
EBITDA	-7	-9	-13	-15	-17	-22	-32	-31	-38	-
Interest Expense	0	0	0	0	0	0	0	-	-	0
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-10	-12	-15	-17	-23	-33	-31	-38	-38
Income Tax Expense	0	0	1	0	0	0	0	0	0	1
Net Income	-8	-10	-12	-15	-17	-23	-33	-32	-39	-39
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Citius Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-9	-9	-8	-10	-11	-10	-11	-9	-7
Operating Cash Flow	-6	-6	-7	-8	-5	-4	-4	-5	-11
Investing Cash Flow	-	-	-	-	-5	-5	-	-	-
Financing Cash Flow	0	-	-	13	-3	2	3	11	15
Change in Cash	-6	-6	-7	5	-14	-2	-1	6	-1

Citius Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Net Income	-10	-12	-15	-17	-23	-33	-32	-39	-39
Operating Cash Flow	-7	-11	-12	-16	-24	-28	-29	-28	-26
Investing Cash Flow	0	0	0	0	-40	-	-	-5	-5
Financing Cash Flow	10	17	11	22	120	0	13	9	33
Change in Cash	2	5	-1	5	56	-28	-15	-23	1

Global Institutional Holdings in Citius Pharmaceuticals Inc

Funds	Holdings
UBS Group AG	1.13%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	1.08%
Heights Capital Management Inc	0.94%
Vanguard Group Inc	0.47%
Geode Capital Management, LLC	0.45%

See all

Insights on Citius Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Insmed Incorporated has given 148.8% return, outperforming this stock by 228.8%
NO EFFECT
Against Peers
In the last 3 years, Insmed Incorporated has given 771.1% return, outperforming this stock by 867.2%
NEGATIVE IMPACT
Price Dip
In the last 1 month, CTXR stock has moved down by -38.3%

About Citius Pharmaceuticals Inc

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.

Organisation	Citius Pharmaceuticals Inc
Headquarters	11 Commerce Drive, Cranford, NJ, United States, 07016
Industry	Health Technology
CEO	Mr. Leonard L. Mazur
E-voting on shares	Click here to vote

Key Management of Citius Pharmaceuticals Inc

Name	Title
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary
Mr. Jaime Bartushak	Chief Business Officer & CFO
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman
Mr. Gary F. Talarico	Executive Vice President of Operations
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications

FAQs

What is Citius Pharmaceuticals Inc share price today?

Citius Pharmaceuticals Inc share price today is $0.76 as on January 1, 2026 at 2:29 am IST at the close of the market. Citius Pharmaceuticals Inc share today touched a day high of $0.8 and a low of $0.76.

What is the 52 week high and 52 week low for Citius Pharmaceuticals Inc share?

Citius Pharmaceuticals Inc share touched a 52 week high of $4.51 on January 2, 2025 and a 52 week low of $0.63 on December 24, 2025. Citius Pharmaceuticals Inc stock price today i.e. January 1, 2026 at 2:29 am IST is closed at $0.76,which is 83.15% down from its 52 week high and 20.63% up from its 52 week low.

What is Citius Pharmaceuticals Inc's market capitalisation today?

Citius Pharmaceuticals Inc market capitalisation is $0.00T as on January 1, 2026 at 2:29 am IST.

How to invest in Citius Pharmaceuticals Inc Stock (CTXR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Citius Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Citius Pharmaceuticals Inc Shares that will get you 1.9737 shares as per Citius Pharmaceuticals Inc share price of $0.76 per share as on January 1, 2026 at 2:29 am IST.

What is the minimum amount required to buy Citius Pharmaceuticals Inc Stock (CTXR) from India?

Indian investors can start investing in Citius Pharmaceuticals Inc (CTXR) shares with as little as ₹90.168 or $1 (as of January 2, 2026 at 5:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹901.68 in Citius Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on January 2, 2026 at 5:40 pm IST). Based on Citius Pharmaceuticals Inc share’s latest price of $0.76 as on January 1, 2026 at 2:29 am IST, you will get 13.1579 shares of Citius Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Citius Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Citius Pharmaceuticals Inc stock has given -96.95% share price returns and 22.84% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?